Results 111 to 120 of about 26,283,235 (262)
Clinical laboratory COVID-19 response call : June 28, 2021 [PDF]
CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).
core
Molecular Oncology, EarlyView.Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source
Clinical laboratory COVID-19 response call : April 18, 2022
CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19). These Clinical Laboratory COVID-19 Response Calls take place on
core
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Clinical laboratory COVID-19 response call : July 12, 2021 [PDF]
CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).
core
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner +14 more
wiley +1 more source
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology, EarlyView.MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
Clinical laboratory COVID-19 response call : January 24, 2022
CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).
core
Clinical laboratory COVID-19 response call : July 6, 2020 [PDF]
CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).
core